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In frontotemporal dementia (FTD), age at disease onset (AAO) is unpredictable in both early and 
late-onset cases; AAO variability is found even in autosomal dominant FTD. The present study was 
aimed at identifying genetic modifiers modulating AAO in a large cohort of Italian FTD patients. 
We conducted an association analysis on 411 FTD patients, belonging to 7 Italian Centers, and for 
whom AAO was available. Population structure was evaluated by principal component analysis to 
infer continuous axes of genetic variation, and single linear regression models were applied. A 
genetic score (GS) was calculated on the basis of suggestive single nucleotide polymorphisms 
(SNPs) found by association analyses. GS showed genome-wide significant slope decrease by –
3.86 (95%CI: –4.64 to –3.07, p<2°ø10−16) per standard deviation of the GS for 6 SNPs mapping to 
genes involved in neuronal development and signaling, axonal myelinization, and 
neurotransmission. An increase of the GS was associated with a decrease of the AAO. Our data 
indicate that there is indeed a genetic component that underpins and modulates up to 14.5% of 
variability of AAO in Italian FTD. Future studies on genetic modifiers in FTD are warranted. 
 
 























Frontotemporal dementia (FTD) is a neurodegenerative disorder characterized by behavioral 
abnormalities, impairment of executive functions, and language deficits [1]. Mutations in the 
Granulin (GRN) , C9orf72 , or Microtubule Associated Protein Tau (MAPT) , and, recently, the 
TANK binding kinase 1 (TBK1 ) genes drive up to∼ 40% of Mendelian cases [2]; for the 
remaining cases, multiple loci and genes appear to influence FTD risk with rather small effect 
size [3, 4]. 
 
The clinical, pathological, and genetic profiles, as well as the age at onset (AAO), are highly 
heterogeneous in FTD. FTD is considered the most common neurodegenerative dementia in the 
young adulthood along with Alzheimer’s disease with a mean onset age between late 50 s and early 
60 s [5]; however, recent reports suggested an increased span in the range of disease onset up to 
>70 years of age [6, 7]. Similarly, variability of AAO is found in autosomal dominant FTD [8–11]. 
 
Genetic variants may influence and/or modulate specific features of a disorder, including disease 
onset and progression. Indeed,AAO, which is rather unpredictable in FTD, might associate with a 
genetic structure that contributes to an earlier or later disease development. 
We recently carried out a genome-wide association study (GWAS) in FTD patients from Italy, and 
identified an extended number of genetic risk factors associated with disease in the Italian 
population [3]. 
 
In the present work, we sought to explore whether such risk factors might influence disease onset in 
the Italian FTD population by searching for genetic variants associated with age at disease onset, 
and computing a genetic risk score (GS) to stratify age of disease susceptibility. 
 METHODS 
Subjects 
 Genotyping data of DNA samples diagnosed with FTD were available to us from the FTD-GWAS 
dataset [4]. Our association analysis was carried out on 411 FTD patients, belonging to 7 Italian 
Centers (see Supplementary Table 1), already included in our previous study [3] and for whom 
AAO was available. 
Diagnosis of FTD, and FTD subtypes (i.e., behavioral variant FTD and primary progressive 
aphasia), was made according to current clinical criteria [12,13]. Estimated AAO was referred by 
the proxy caregiver by a semi-structured interview, and carefully recorded. 
Informed consent and Ethic Committee approval were obtained at the individual sites and each 
center provided consent for their use for the purposes of this study. The cases were collected and 
genotyped at the University College London (UCL) by means of Illumina human 660K-Quad 
Beadchips assayed on the Illumina Infinium platform (Illumina, San Diego,CA, USA); 657231 
single nucleotide polymorphisms (SNPs) were genotyped. 
 
Quality control 
 Quality control (QC) was performed at both markers (per-marker) and samples (per-individual) 
level, as previously illustrated by Anderson et al. [14]. Specifically, per-marker QC of the data 
consisted of three different steps, namely 1) the identification and removal of SNPs with an 
excessive missing genotype (> 0.1); 2) the identification and removal of SNPs with significant 
deviation from Hardy-Weinberg equilibrium (HWE) (p≤ 0.001); and 3) the removal of all makers 
with a very low minor allele frequency (MAF) (MAF < 0.05). Per-individual QC of the data 
consisted in identifying and removing of 1) the individuals with discordant sex information; 
2) the individuals with outlying missing genotype (genotype failure rate≥ 0.03); and 3) 
heterozygosity rate°æ 3 standard deviations from the mean. 
Principal component analysis 
 Population structure was evaluated by principal component analysis (PCA) to infer continuous 
axes of genetic variation. PCA was processed on the similarity matrix between any two individuals 
(i, j),  based on the genome-wide average proportion of alleles sharing identical by state (IBS) and 
using for the SNPs the additive coding (0, 1, 2 minor frequency alleles). We excluded outlier 
samples, defined as individuals exceeding a default number of standard deviations (6.0) from the 
whole sample. The 657, 231 SNPs were reduced to 125,902 SNPs for IBS computation, by 
trimming the dataset so that no pair of SNPs (within a given number of base-pairs) had Linkage 
Disequilibrium (LD,measured by r2) greater than 0.2. PC axes were considered significant 
according to Tracy-Widom statistic [15]. 
 
 
Linear regression model 
 We used markers of highest quality to impute with Minimac [16] approximately 2.5 million SNPs, 
based on European-ancestry haplotype reference (HapMap II CEU population build 36, release 22). 
Imputed SNPs with a MAF< 0.01, and with low imputation quality (Rsq < 0.50) were removed (for 
Minimac protocol details, see http://genome.sph.umich.edu/wiki/Minimac : 1000 Genomes 
Imputation Cookbook). 
We then tested each available SNP (observed and imputed) to assess the association withAAOby 
usingp -values (two-tailed) from a linear regression model (LRM), with an additive coding per 
SNP, and adjusting for sex and significant principal components. The fixed threshold for genome-
wide significance was set at the consensus level of p <5°ø 10−8 . We defined SNPs as suggestive if 
5°ø 10−5  > p >5°ø 10−8 . We performed this analysis in presence and absence of apolipoprotein E 
(APOE ) _ 4 homozygous carriers and also used APOE _ 4 as a covariate to assess and/or 
correct for any potential influence of this genetic marker on final results. 
 
 Genetic score computation 
 The suggestive SNPs obtained by association analysis were used to calculate a weighted genetic 
risk score (GS). Specifically,GSwas defined as sum of the number of minor frequency alleles (0 
(not present),1 (heterozygous), 2 (homozygous)) per suggestive SNPs weighted by their log OR, 
i.e., the odds ratio (OR) estimate derived from our previous case-control study [4]. Thus, the 
weights were determined independently from the genetic-AAO association of this work, eluding 
over fitting biases. We defined three trimming rules for inclusion of SNPs in the GS: 1) SNPs with 
moderate to high case-control signal (logORs > log(1.2)), recoding all negative logOR into positive 
logOR on the basis of the risk allele; 2) SNPs observed or imputed with high quality (Rsq > 0.9); 
and 3) SNPs in Linkage Equilibrium (LE). For SNPs in Linkage Disequilibrium, the SNP with the 
lowest AAO p -value was selected. 
Then, GSwas standardized as Z  = (GS-mean(GS))/standard deviation (GS), and LRM of AAO on 
the standardized GS was performed adjusting for the following covariates: i) sex, ii) population 
structure (measured by geographical zone such as North, Center, South and/or by significant 
principal components), iii) type of FTD (5 subtypes: bvFTD, SD,PNFA, FTD-MND, and FTD 
spectrum), and iv) APOE (0 = _ 23_ 23, 1 = _ 23_ 4, 2 = _ 4_ 4). QC analysis and statistical 
analyses were performed by free software PLINK [17] and R [18], respectively. Gene annotation on 
top-associated markers was performed by R package NCBI2R [19]. 
 
RESULTS 
 AAO was available for 411 out of 532 FTD patients that underwent Italian GWAS [3]. The 
mean AAO was 63.7°æ 20.7 (range, 36.0 – 82.0) with male/female ratio 187/224 (male 45.5%). 
Two hundred-fifty patients came from Northern Italy, 49 patients from the Center, and 112 from 
Southern Italy. Out of 411 FTD patients, 307 had bvFTD, 82 PPA, 20 FTD-MND, and 2 belonged 
to the FTD spectrum. A minority of cases, for which FTD genes had been screened, carried variants 
in MAPT  (n  = 4), GRN (n  = 38), and C9orf72  (n  = 11). Two MAPT  and one 
GRN  variants are now reported to be pathogenic, whilst the remaining ones are common 
polymorphisms; considering that the mutations have very small frequency in the current sample set, 
thus they are negligible, and that, together with the C9orf72 positive cases they were kept in the 
previous studies [3, 4], we also kept and included them in our current analysis. 
Population structure through PCA showed genetic pattern that correlated with geographical 
provenience (i.e., North, Center, and South), as displayed in the scatter plot of the first two PCs 
(Fig. 1). According to Tracy-Widom statistics, that tests additional population structure of the first 
10 eigenvalues, only the first PC (TW1 = 5.03480, p  < 0.001)was deemed significant and used as 
covariate in AAO association analyses to correct for population stratification. 
By single linear regression analysis, we identifie suggestive evidence (p <5°ø 10−5 ) of an 
association with AAO for 127 SNPs (using sex and first PC as covariates), while none achieved 
genome-wide significance (see Manhattan plot in Fig. 2). 
As defined in the method section, log OR weighted GSwas computed after three trimming rules 
identifying 6 SNPs mapping to the following loci: intergenic region on chromosome (chr) 1 
encompassing the G protein-coupled receptor 137B  (GPR137B ) and the Endoplasmic Reticulum 
Oxidoreductase Beta (ERO1B ) genes; chr 2, intronic to the Hypocalcinlike1 (HPCAL1 ) gene and 
LOC730100  (which is proximal to Neurexin 1 (NRXN1 )); chr 9, intronic to the Protein Tyrosine 
Phosphatase, Receptor Type D (PTPRD ) gene, and; chr 13, in LOC101926897 , LOC105370219  
and LOC105370220 , and LOC105370290  and LINC00375  (Table 1). 
Linear regression analysis of AAO based on the score effect of these 6 markers (GS), adjusted for 
covariates (see method), showed genome-wide significant slope decrease by –3.68 (95%CI: –4.52 
to –2.84, p <2°ø 10−16 ) per standard deviation of the GS meaning that an increase of the GS was 
associated with a decrease of the AAO. When we excluded APOE _ 4 homozygous carriers from 
our analysis there still was a similar genome-wide significant slope decrease, and when using 
APOE _ 4 as a covariate results were again not affected indicating that effect on AAO is 
independent from the APOE  status.  
Of note, considering all the predictors (GS + covariates) we found that total contribution (R2 ) to 
AAO variance was ∼ 22% where only gender and PC1 were the actual significant covariates 
contributing to AAO variance in addition to GS in the value of ∼ 7%. 
Therefore and in summary, the AAO variance explained by GS only (excluding the covariates) 
reached ∼ 14.5%. The AAO-GS association is visualized and summarized in Fig. 3 and Table 2, 
respectively. For overfitting control, we also computed the prediction error (PE) by Leave-One-Out 
method (K = n), and K= 10-fold Cross-Validation: the corresponding R2  were 13.7%, and 14.2%, 
respectively. Finally, backward stepwise analyses in the GS showed that 7.8% of this signal was 
driven by the AAO-associated SNPs in HPCAL1  and PTPRD . 
 
DISCUSSION 
 FTD is a complex disorder that encompasses heterogeneous phenotypes and variable AAO. Our 
current study supports the notion that individual genetic background modifies age at disease onset 
and modulates disease presentation. 
We computed a genetic score (GS) able to weight the genetic contribution to the variability of AAO 
in FTD (the higher the GS, the lower the age at disease onset). Particularly, the GS of six SNPs 
indicated significant genetic contribution for up to 14% of variability of AAO in FTD. This is 
remarkable as it suggests that the genetic component underlying variability of AAO has a robust 
implication in FTD comparatively, for example, to Parkinson’s disease for which a similar study 
approach revealed that their GS only contributed to 0.6% of variability of AAO [20]. Similar 
observations for Parkinson’s disease were made in other studies [21]. Conversely, a recent study in 
Alzheimer’s disease showed that eitherAPOE or a combination of nine loci contributed 
to 3.7% and 2.2% of variability of AAO, respectively [22], whereas in our current study the 
contribution of the APOE  status was basically negligible. Taken all this together, we gather that in 
FTD the genetic component appears to have a stronger influence on AAO prediction than in 
Parkinson’s disease and in Alzheimer’s disease [20–22]. 
Considering the 6 loci that we identified influencing AAO in FTD, the literature suggests, 
particularly for NRXN, HPCAL1 , and PTPRD , a direct link with the biology of the brain through 
calcium-mediated neuronal signaling, development of neocortical regions as well as axonal 
myelination and glutamatergic/GABAergic synapsis, respectively [23–26]. 
 
It is interesting to gather that variability in these genes, and their associated functions and 
processes, could underpin the modulation of disease onset in FTD. In addition, it is noteworthy that 
GPR137B was previously shown to associate with modulation of drug-response in schizophrenia, 
particularly mediating effect of antipsychotics on working memory [27]. 
NRXN1 has been implicated in neocortical development and aging [23], andNRXN1 genetic 
variations affect the risk of autism and schizophrenia [28, 29]. 
Of note, we reported the locus including NRXN1 already in our previous work highlighting novel 
suggestive loci for FTD in the Italian population [3]; here, we provide further support for this 
association and expand on its potential implication in driving AAO. All the more, in the previous 
[3] and the current work, the OR associated with SNPs at the NRXN1  locus were among the 
highest, 2.5 and 1.64, respectively, suggesting that variability at this locus might associate with 
disease as well as AAO with a moderate effect size. Moreover, a close relationship 
between NRXN1 and one of the main actors of FTD pathogenesis, namely TDP-43 protein, was 
recently shown: a novel miRNA (miR-NID1) processed from the intron 5 of NRXN1  is able to 
repress NRXN1 expression by binding to TDP-43, thus this complex (TDP-43 + miR-NID1) might 
hold relevance and be implicated in FTD-TDP pathology [30].  
 
In the same view, HPCAL1 , a gene encoding the HPCAL1 protein that modulates calcium-
mediated neuronal signaling [25], has been implicated in the risk of Alzheimer’s disease and autism 
development [31, 32], thus supporting a general involvementin neurodegenerative disease, 
including FTD, and PTPRD has been associated with obsessive-compulsive disorders [26]. 
Currently, there are no known relationships with conditions affecting the brain for ERO1B  
(involved in protein oxidative folding) [33], while the role of LOC101926897 , LOC105370219 
and LOC105370220 , and LOC105370290  and LINC00375  appear to be more complicated to 
infer, given that the latter are non-coding RNAs, which belong to a different group of cellular 
functional elements, rather involved in transcription and/or translation regulation. Nevertheless, this 
piece of data raises the awareness that non-coding functional elements are important and deserve 
attention, fostering the implementation of study designs and analysis strategies that focus and shed 
light on such regulatory elements. 
Our study overall suggests and supports the relevance of factors that modulate features of FTD; this 
goes along with other examples of common risk variants acting as genetic modifiers in Mendelian 
FTD such as TMEM106B . The latter has been reported as a genetic modifier affecting both AAO 
and circulating levels of progranulin in FTD patients carrying Granulin  mutations [34, 35]. 
Another example of genetic modifiers of AAO is the one recently reported in PSEN1 -related 
Alzheimer’s disease [36]. 
 
In summary, we herein describe an additive effect of 6 SNPs and their likely implication in 
modulating disease onset in Italian FTD patients, for which we further considered the genetic 
make-up of Italian regions (i.e., North, Center, and South) as possible confounder in the analyses, 
when a Mendelian trait was excluded a priori . 
Our data indicate that there is a genetic component that underpins and modulates up to 14.5% of 
variability of AAO in Italian FTD. 
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